Please assess the completion status of the following clinical trial:

Trial Title: BAY81-8973 Pediatric Safety and Efficacy Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* PTPs (previously treated patients): aged \<= 12 years~* PUPs (previously untreated patients) / MTPs (minimally treated patients): aged \< 6 years~* Severe hemophilia A defined as \< 1% FVIII concentration (FVIII:C)~* PTPs: \>= 50 exposure days (EDs) with any FVIII concentrate, no current evidence of inhibitory antibody, and no history of FVIII inhibitor formation~* PUPs: no prior exposure to any FVIII product~* MTPs: having no more than 3 EDs with any FVIII product, no current evidence of inhibitory antibody and no history of FVIII inhibitor formation~Exclusion Criteria:~* With another bleeding disorder that is different from Hemophilia A~* With thrombocytopenia (platelet count \< 100 000/mm\^3)~* Creatinine \> 2x upper limit of normal or Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) \> 5x upper limit of normal~* Without a negative inhibitor testing at screening (except for PUPs)~* Receiving chemotherapy, immune modulatory drugs, has received another investigational FVIII product within the last month, or received another experimental drug within the last 3 months~* Requires any pre-medication to tolerate FVIII treatment~* Known hypersensitivity to active substance, mouse, or hamster protein

- Gender: MALE
- Minimum Age: 0 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- PTPs 0-12 years (Type: EXPERIMENTAL): Previously treated patients (PTPs) aged below 12 years received BAY81-8973 25-50 IU/kg at least 2x/week for 6 months and at least 50 exposure days (EDs) in main study - Part A. Participants having reached at least 50 EDs in main study - Part A were offered participation in an open label extension study (optional). Participants who transitioned from main study - Part A to the extension study received BAY81-8973, 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part A and extension study).
- PUPs/MTPs 0-<6 years (Type: EXPERIMENTAL): Previously untreated patients (PUPs) or minimally treated patients (MTPs, patients who had no more than 3 exposure days (EDs) with any FVIII product) received BAY81-8973 15-50 IU/kg at least 1x/week for at least 50 EDs or until inhibitor development in main study - Part B. Participants having reached at least 50 EDs in main study - Part B were offered participation in an open label extension study and received BAY81-8973 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part B and extension study); participants who developed an inhibitor in main study - Part B were offered participation in open label extension study and received Immune Tolerance Induction (ITI) treatment with BAY81-8973 until successful eradication of the inhibitor, or until failure, for approximately 18 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).